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Abbreviations and Acronyms
AD Alzheimer’s disease
ANP Atrial natriuretic peptide
ARVC Arrhythmogenic right ventricular Cardiomyopathy
AT1/2R Angiotensin type 1/2 receptor
ATII Angiotensin II
BNP Brain natriuretic peptide
DCM Dilated cardiomyopathy
ECM Extracellular matrix
HF Heart failure
IL1β Interleukin 1 β
LV Left ventricular
MCP-1 Monocyte chemoattractant protein-1
MIP 1α Macrophagic inflammatory protein 1 α
MMP-9 Matrix metalloproteinase-9
PIIINP N-terminal type III collagen peptide
RAAS Renin-angiotensin-aldosterone system
RyR2 Ryanodine receptor 2
SERCA Sarco-/endoplasmic reticulum Ca2+-ATPase
SR Sarcoplasmic reticulum
TIMP-1 Tissue inhibitor of metalloproteinase-1
TNFα Tumor necrosis factor
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Dilated cardiomyopathy (DCM) is characterized by dilated left ventricle with sys-
tolic dysfunction that is not caused by ischemic or valvular heart disease.
The hallmark pathophysiologic feature of DCM is systolic dysfunction of the left 
or both ventricles. Reduced sarcomere contractility increases ventricular volumes to 
maintain cardiac output through the Frank-Starling mechanism, producing the thin- 
walled dilated LV appearance that is observed in overt DCM.
Frank and Starling demonstrated that increased ventricular preload augments 
contractility, but excessive pressure and volume induces a plateau and then a reduc-
tion in myocardial contraction [1]. Abnormal hemodynamics leads further to left 
ventricular (LV) remodeling.
Cardiac remodeling in response to an inciting myocardial insult or an underly-
ing genetic abnormality has been classically considered the pathognomonic aspect 
of DCM.
3.1  Ventricular Remodeling in DCM
The term ventricular remodeling refers to alteration in ventricular architecture, with 
associated increased volume and altered chamber configuration, driven on a histo-
logic level by a combination of pathologic myocyte hypertrophy, myocyte apopto-
sis, myofibroblast proliferation, and interstitial fibrosis.
Pathologic LV remodeling is closely linked to activation of a series of neuroen-
docrine, paracrine, and autocrine factors, which are upregulated after myocardial 
injury and in the setting of increased LV wall stress and hemodynamic derange-
ment. Contributing factors include the renin-angiotensin-aldosterone (RAA) axis, 
the adrenergic nervous system, increased oxidative stress, pro-inflammatory cyto-
kines, and endothelin. Both RAA system inhibition and beta-adrenergic blockade 
have shown to markedly attenuate or reverse LV remodeling in patients with heart 
failure and LV dilation.
Left ventricular remodeling results in characteristic alterations of left ventricular 
function that can be described in terms of altered left ventricular pressure-volume 
relationship. Left ventricular dilatation and reduced systolic function induce a right-
ward displacement of the pressure-volume curve with increased left ventricular end- 
diastolic volumes and pressures. Despite increased preload, stroke volume may be 
reduced, and end-systolic pressure to volume ratio (index of contractility) is 
depressed. In addition to this, diastolic dysfunction due to incomplete relaxation 
after disturbed excitation-contraction coupling processes and increased stiffness 
due to altered extracellular matrix composition cause an additional upward shift of 
the pressure-volume relation.
When the preload reserve is exhausted, the stroke volume becomes sensitive to 
alterations in the afterload. It depends on blood viscosity, vascular resistance, vas-
cular distensibility, and mainly myocardial wall tension.
Calculations of myocardial wall tension are defined by the Laplace equation and 
are expressed in terms of tension, T, per unit of cross-sectional area (dynes per cen-
timeter [dyn/cm]).
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Within a cylinder, the law of Laplace states that wall tension is equal to the pres-
sure within a thick-walled cylinder times the radius of curvature of the wall:
 T P R h= ´ /  
where T is wall tension (dyn/cm), P is pressure (dyn/cm2), R is the radius (cm), and 
h is wall thickness.
Two fundamental principles stem from the relationship between the geometry of 
the ventricular cavity and the tension on its muscular walls: (1) dilatation of the 
ventricles leads directly to an increase in tension and (2) an increase in wall thick-
ness reduces the tension on any individual muscle fiber. Therefore, ventricular 
hypertrophy reduces afterload by distributing tension among more muscle fibers.
Dilatation of the heart decreases cardiac efficiency as measured by myocardial 
oxygen consumption unless hypertrophy is sufficient to normalize wall stress. In 
HF, wall tension (or stress) is high, and thus, afterload is increased. The energetic 
consequences of the law of Laplace can have some role in progressive deterioration 
of energy-starved cardiac myocytes in the failing heart.
3.2  Genetic Pathophysiology and New Possible Proteins 
Involved in DCM [2]
A great diversity of pathogenetic pathways has been hypothesized to explain the 
development of DCM, depending on the affected genes and the dislodged intracel-
lular structures or pathways.
The wide variety of genes involved in the pathophysiology of DCM gives an 
insight to think of DCM as a group of diseases, instead of a single form of cardio-
myopathy (Fig. 3.1).
Genetic mutations suggest several mechanisms of ventricular dysfunction in 
DCM as follows:
• Deficit in force generation (sarcomere DCM): Mutations within genes encoding 
titin, myosin, actin, troponin, and tropomyosin result in the expression of abnor-
mally functioning proteins, thus leading to myocardial dysfunction and 
DCM. Sarcomere gene mutations are the most frequent causes of DCM with 
truncating mutations in titin (TTNtvs) occur in 25% of end-stage disease and in 
15% of ambulatory DCM patients [3, 4].
• Defects in nuclear envelope (laminopathies): These diseases are characterized by 
variable degrees of heart and skeletal muscle involvement. Mutations involve Lamin-
A/C and emerin coding genes. Dominant Lamin A/C mutations occur in approxi-
mately 6% of DCM cases and are far more common in DCM with conduction system 
disease [5]. Electrophysiological abnormalities (conduction system block and atrial 
fibrillation) often precede DCM that relentlessly progresses to HF [6, 7]. The severity 
of the associated skeletal myopathy is variable. Most Lamin A/C mutations cause 
haploinsufficiency, and mouse models of these mutations demonstrate inadequate 
response to mechanical strain, which may promote premature cardiomyocyte death.
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• Deficit in force transmission (cytoskeletal cardiomyopathies): Mutations involv-
ing protein members of the cytoskeletal apparatus, like filamins, dystrophin, des-
min, d-sarcoglycan, and vinculin, are responsible for muscular dystrophies, 
which are often associated with DCM.
• Filamins are large cytoskeletal actin cross-linking proteins that stabilize the actin 
filament networks and link them to the cell membrane by binding transmem-
brane proteins and ion channels [8]. Filamin C encodes a large protein (2725 
amino acids) primarily expressed in the cardiac and skeletal muscle that interacts 
with sarcomeric proteins in the Z-disc and the sarcolemma. Filamin C truncation 
variants are associated with a severe arrhythmogenic DCM phenotype in the 
absence of overt skeletal muscle disease.
• Deficit in protein post-translational modifications (glycosylation processes- 
cardiomyopathies): An example comes from dolichol kinase gene mutations, 
resulting in impairment of protein glycosylation processes inside the cell organ-
elles, thus manifesting as syndromic conditions with hypertrophic phenotype 
and as non-syndromic DCM phenotype [9].
• Impaired cell-to-cell adhesion (desmosomal cardiomyopathies): Mutations in 
genes encoding desmosomal proteins are responsible for arrhythmogenic right 
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Fig. 3.1 Cardiomyocyte compartments contributing to genetically mediated dilated cardiomyop-
athy. See Legend for abbreviations and acronyms. (Adapted from McNally EM, Mestroni L, 
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ventricular Cardiomyopahty (ARVC) and also for DCM, with a prevalence of up 
to 13% in a DCM cohort [10].
• Deficit in energy production (mitochondrial cardiomyopathies): They are char-
acterized by defects in the oxidative phosphorylation that result in deficient 
energy production in the form of ATP. They include hypertrophic, dilated, and 
LV non-compaction phenotypes.
• Calcium-cycling abnormalities: A DCM mutation has been described in the 
phospholamban gene. Phospholamban is responsible for inhibition of sarco-/
endoplasmic reticulum Ca2+ –ATPase (SERCA) function. Mutations in the gene 
result in increased SERCA inhibition with defective calcium reuptake, with con-
sequent reduction in contractility and heart dilation.
• Ion channel abnormalities: Mutations in ion channel genes (SCN5A, ABCC9) 
are typically associated with a variety of arrhythmic disorders. The ventricular 
dilation and DCM pattern is less common and almost always preceded by 
arrhythmias and/or conduction system defects [11, 12]. The pathogenetic mecha-
nisms are poorly understood.
• Spliceosomal defects: RBM20 is an RNA binding protein involved in alternative 
splicing process. DCM associated with RBM20 mutations is frequently associ-
ated with early onset, severe heart failure, and high arrhythmic potential.
• Epigenetic perturbation: Missense mutation in GATAD1 gene is associated with 
DCM. GATAD1 encodes for a protein that is thought to bind to a histone modi-
fication site that regulates gene expression.
• Protein misfolding disease: Mutations in presenilin genes have been recently 
identified in patients with DCM [13]. Presenilins are also expressed in the heart 
and play a role in heart development. Aβ amyloid is a possible novel cause of 
myocardial dysfunction. Echocardiographic measurements of myocardial func-
tion suggest that patients with Alzheimer’s disease (AD) present with an antici-
pated diastolic dysfunction. As in the brain, A β40 and A β42 are present in the 
heart, and their expression is increased in AD [14].
• RAS-MAPK pathway disruption: Mutations in RAF-1 gene are responsible for 
rare variants of childhood-onset, non-syndromic DCM.
3.3  Molecular Mechanisms of Cardiac Remodeling in HF [15]
DCM is histologically characterized by diffuse fibrosis, compensatory hypertrophy of 
the other myocytes, and myocyte dropout. Myocyte hypertrophy is promoted by cat-
echolaminergic stimulation, stretch activation of integrins by myocyte and fibroblast, 
G protein-mediated intracellular signaling, and micro-RNA networks. A new gene 
expression toward a fetal pattern results in profound morphological rearrangements. 
The rate of myocyte apoptosis and consequently progressive cells lost is increased in 
DCM. This process is partly favored by the elevated expression of fetal genes.
Neurohormonal systems. Acutely reduced cardiac output or vascular underfilling 
leads to baroreceptor-mediated sympathetic nervous activity with elevation of heart 
rate, blood pressure, and vasoconstriction. Although these changes maintain an 
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adequate cardiac output, at the end they lead to vicious circle. Catecholamines promote 
arrhythmias, myocardial ischemia, myocyte hypertrophy, and apoptosis and cause dif-
ferent signal-transduction abnormalities (e.g., beta-1 receptor downregulation) [16].
HF results from increased sympathetic nervous activity, but the renin- angiotensin- 
aldosterone system (RAAS) is also pathologically activated.
Angiotensin II (ATII) is the most powerful mediator of the RAAS. Its activity is 
mediated by two major G protein receptor associated receptors: angiotensin type-1 
and type-2 receptor (AT1R and AT2R). AT1R is expressed mainly in the vascula-
ture, kidney, adrenal cortex, lungs, and brain, and its activation promotes vasocon-
striction; AT2R is mainly expressed in the myocardium and promotes vasodilatation 
and antiproliferative, anti-oxidative, and anti-inflammation effects.
ATII contributes to the increased activity of the sympathetic nervous system by 
stimulating the adrenal glands and the juxtaglomerular apparatus of the kidney with 
resulting elevation of plasma renin levels.
Furthermore, ATII stimulates adrenal secretion of aldosterone which, together 
with vasopressin, reduces renal excretion of water and sodium [17], configuring an 
inappropriate ADH secretion syndrome.
Finally, ATII contributes to cardiac remodeling promoting myocyte hypertrophy 
and apoptosis and structural and biochemical alterations in the ECM [18, 19].
Natriuretic peptides. Natriuretic peptides are hormones produced by the heart. 
The most important ones are atrial natriuretic peptide (ANP), mainly produced in 
the atria, and B-type natriuretic peptide (BNP) which is mainly released by ven-
tricular myocardium. They are released in response to myocardial stretch and act as 
counter-regulatory hormones promoting natriuresis, diuresis, and vasodilation. 
Their plasma concentrations raise in proportion to HF severity and are consolidated 
markers of poor prognosis in overt HF.
Inflammation. Inflammation may also play a role in pathophysiology of 
DCM. Many studies have shown an increase in different inflammatory mediators 
(e.g., tumor necrosis factor α (TNFα), interleukin (IL) 1beta). IL-2, IL-6, Fas ligand, 
monocyte chemoattractant protein-1 (MCP-1), and macrophage inflammatory pro-
tein α (MIP-1α) in HF have also been renamed as an inflammatory disease.
TNFα, for example, has a negative inotropic toxic effect on the myocardium that 
is connected to adverse ventricular remodeling in DCM.
Extracellular matrix. The extracellular matrix in the heart provides the scaffold-
ing within which contractile cardiomyocytes are housed; it contains a basement 
membrane, collagen network, proteoglycans, and glycosaminoglycans. Of the dif-
ferent types of collagens, type I and III collagens are the predominant forms found 
in fibrils deposited in scar tissue after myocardial injury, more specifically demon-
strated in myocardial infarction models. These collagens are initially synthesized by 
cardiac fibroblasts as procollagen precursors before both the N-terminal and the 
C-terminal are cleaved by proteinases, and then the resulting tropocollagen is 
assembled into mature fibrils. Markers of collagen turnover such as serum N-terminal 
type III collagen peptide (PIIINP) have been associated with increased mortality 
and hospitalization rates, and procollagen type I and PIIINP levels appeared to 
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decrease following aldosterone antagonist therapy in chronic HF patients [20]. In 
the 967 Framingham subjects without HF, PIIINP levels were not independently 
associated with LV mass, fractional shortening, end-diastolic dimensions, or left 
atrial size [21].
The extracellular matrix is a rather dynamic system that is constantly turned 
over. In the setting of cardiac or extracardiac injury, regulation of extracellular 
matrix likely plays an important role in ventricular remodeling and fibrosis. For 
example, bone morphogenetic protein 1, a C-proteinase, plays a crucial role in the 
processing of extracellular matrix proteins and collagen deposition and regulation 
of excessive collagen deposition in fibrosis after tissue injury [22]. Recent studies 
have found that gene expression of tissue inhibitor of metalloproteinases-1 (TIMP- 
1) and matrix metallopeptidase-9 (MMP-9) was significantly increased in the bor-
der zone of myocardial infarct models as well as ischemic HF models in rats and 
that treatment with antifibrotic therapy can prevent the upregulation of MMP-9, 
ultimately leading to suppression of collagen deposition [23, 24]. Interestingly, con-
centrations of TIMP-1 appeared to correlate with diastolic LV dysfunction [25]. In 
a multimarker analysis of HF patients, a panel that included TIMP-1 as well as 
NT-proBNP, hs-TnT, growth differentiation factor 15, and insulin-like growth 
factor- binding protein 4 had the best performance in predicting all-cause mortality 
at 3-year follow-up.
Calcium. Cytoplasmic Ca2+ has a key role in cardiac contraction triggering the 
interaction of the myosin-thick and actin-thin myofilament. During the depolariza-
tion of the myocyte, Ca2+ enters the myocyte through L-type Ca2+ channels known 
as transverse tubules, which are close to the sarcoplasmic reticulum (SR) and stimu-
lates the release of much greater quantities of Ca2+ from the SR into the cytoplasm 
through the Ca2+ release channels, the ryanodine receptors (RyR2). After reaching a 
critical concentration, the cytoplasmic Ca2+ activates the contractile system of the 
myocyte. The sarco-/endoplasmic reticular adenosine triphosphate-driven [Ca2+] 
(SERCA2a) pump returns cytoplasmic Ca2+ to the SR against a concentration gradi-
ent, and this ends contraction and initiates myocyte relaxation.
Several abnormal Ca2+ cycling may be observed in HF. A first condition is a dia-
stolic leak of Ca2+ through altered RyR2 with the reduction of the Ca2+ content of 
the SR and then a reduction of Ca2+ that can be released during activation [26]. 
Some have attributed this mechanism to the hyper-phosphorylation of RyR2 at ser-
ine 2808 by phosphokinase A [27], others to the phosphorylation at serine 2814 by 
another enzyme, Ca2+/calmodulin-dependent protein kinase II [28].
Another alteration of calcium metabolism is due to a loss of function of the 
SERCA2a pump with a reduction of Ca2+ content of cardiac SR. Phospholamban is 
SERCA2a-protein regulator. In the dephosphorylated state, phospholamban inhibits 
SERCA2a. Stimulation of b-adrenergic receptors normally causes the phosphoryla-
tion of phospholamban and thereby disinhibits SERCA2a, enhancing both cardiac 
contraction and relaxation. For the desensitization of myocardial b-receptors that 
occurs in HF, this mechanism provided by adrenergic stimulation may be reduced 
in this condition [29].
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